Maxim Group Reiterates Buy Rating for Vyome (NASDAQ:HIND)

Vyome (NASDAQ:HIND)‘s stock had its “buy” rating reiterated by Maxim Group in a research note issued on Thursday, MarketBeat Ratings reports. They currently have a $15.00 target price on the stock. Maxim Group’s price objective points to a potential upside of 179.85% from the stock’s previous close.

Several other analysts also recently issued reports on the stock. Citigroup raised shares of Vyome to a “buy” rating in a research note on Thursday. Wall Street Zen lowered shares of Vyome from a “hold” rating to a “sell” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Strong Buy” and an average price target of $15.00.

Vyome Price Performance

HIND opened at $5.36 on Thursday. The firm has a market cap of $3.61 million, a PE ratio of -0.01 and a beta of 1.05. Vyome has a fifty-two week low of $5.04 and a fifty-two week high of $720.00.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.